J&J partners with Apple for ECG monitoring projectApple has a new big pharma partner to help put its new Apple Watch with built-in electrocardiogram (ECG) Share XJ&J partners with Apple for ECG monitoring projecthttps://pharmaphorum.com/news/jj-partners-with-apple-for-ecg-monitoring-project/
United Neuroscience inches closer to Alzheimer’s vaccine prizeA vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to Share XUnited Neuroscience inches closer to Alzheimer’s vaccine prizehttps://pharmaphorum.com/news/united-neuroscience-alzheimers-vaccine/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
Pfizer set for July FDA verdict on rare heart disease drugPfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after Share XPfizer set for July FDA verdict on rare heart disease drughttps://pharmaphorum.com/news/pfizer-set-for-july-fda-verdict-on-rare-heart-disease-drug/
IFPMA’s new code bans all gifts – no exceptions!The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has published its new code of practice, introducing a Share XIFPMA’s new code bans all gifts – no exceptions!https://pharmaphorum.com/news/ifpmas-new-code-bans-all-gifts-no-exceptions/
Daiichi Sankyo takes option on diabetes stem cell start-upJapan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for Share XDaiichi Sankyo takes option on diabetes stem cell start-uphttps://pharmaphorum.com/news/daiichi-sankyo-takes-option-on-diabetes-stem-cell-start-up/
NICE rejects Novartis’ migraine prevention drug AimovigSome migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are Share XNICE rejects Novartis’ migraine prevention drug Aimovighttps://pharmaphorum.com/news/nice-rejects-novartis-migraine-prevention-drug-aimovig/
Sage soars on postpartum depression dataSage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on Share XSage soars on postpartum depression datahttps://pharmaphorum.com/news/sage-soars-on-postpartum-depression-data/
Pair of deals boosts Biogen’s early-stage CNS pipelineBiogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates Share XPair of deals boosts Biogen’s early-stage CNS pipelinehttps://pharmaphorum.com/news/pair-of-deals-boosts-biogens-early-stage-cns-pipeline/
